Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Philippe Backeljauw

Pediatric Endocrinology Cincinnati, OH Medical Doctor

NPI 1770511883 CMS profile 925955

3333 Burnet Ave, Ml 7012, Cincinnati, OH 45229

Open in the dashboard

General payments

$632,427

617 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,407,092 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Philippe Backeljauw of Cincinnati, OH is reported in the CMS Open Payments database as having received $632,427 across 617 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $2,407,092 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $180,492 145
2024 General $114,244 91
2023 General $128,374 149
2022 General $151,087 181
2021 General $24,567 17
2020 General $6,803 7
2019 General $26,861 27

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Philippe Backeljauw
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Philippe Backeljauw were reported at $180,492. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Philippe Backeljauw Pediatric Endocrinology median Middle half National median
2019 $26,861 $196 $68–$845 $163
2020 $6,803 $124 $37–$722 $114
2021 $24,567 $134 $35–$691 $132
2022 $151,087 $177 $47–$726 $149
2023 $128,374 $236 $75–$887 $160
2024 $114,244 $259 $91–$979 $164
2025 $180,492 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. BioMarin Pharmaceutical Inc. $245,196 249 payments
  2. Ascendis Pharma, Inc. $174,157 232 payments
  3. Novo Nordisk Health Care AG $97,846 55 payments
  4. Novo Nordisk Inc $30,378 32 payments
  5. TOLMAR Pharmaceuticals, Inc. $23,353 11 payments
  6. Eton Pharmaceuticals, Inc. $18,155 1 payment
  7. Ipsen Biopharmaceuticals, Inc $11,710 5 payments
  8. Endo Pharmaceuticals Inc. $5,967 8 payments
  9. Tolmar, Inc. $5,928 7 payments
  10. Upsher-Smith Laboratories LLC $4,675 2 payments
  11. Other $15,062 15 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $310,066 131 payments
  2. Consulting Fee $168,276 74 payments
  3. Travel and Lodging $135,155 261 payments
  4. Food and Beverage $10,405 138 payments
  5. Honoraria $7,085 6 payments
  6. Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program $1,155 1 payment
  7. Education $284 6 payments
Products named General payments · program years 2019–2025
  1. SKYTROFA $173,879 229 payments
  2. VOXZOGO 1.2mg Achondroplasia $149,566 128 payments
  3. Norditropin Growth Hormone $52,807 34 payments
  4. FENSOLVI $29,280 18 payments
  5. Norditropin Growth Hormone $19,332 14 payments
  6. Sogroya $19,091 17 payments
  7. VOXZOGO 1.2MG Achondroplasia $18,158 38 payments
  8. KHINDIVI $18,155 1 payment
  9. INCRELEX $18,155 1 payment
  10. Alkindi $18,155 1 payment
  11. Other $35,717 43 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

617 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record